| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 342.38B | 343.07B | 341.99B | 351.79B | 293.83B | 302.41B |
| Gross Profit | 109.27B | 108.14B | 99.52B | 90.78B | 95.41B | 95.15B |
| EBITDA | 49.39B | 51.91B | 44.88B | 36.79B | 48.75B | 49.49B |
| Net Income | 20.90B | 23.39B | 17.75B | 9.36B | 28.00B | 24.53B |
Balance Sheet | ||||||
| Total Assets | 474.44B | 476.21B | 457.36B | 478.34B | 433.21B | 386.79B |
| Cash, Cash Equivalents and Short-Term Investments | 79.84B | 75.54B | 48.68B | 68.08B | 83.12B | 83.68B |
| Total Debt | 113.15B | 110.69B | 105.78B | 142.45B | 109.22B | 98.44B |
| Total Liabilities | 197.73B | 202.35B | 197.41B | 236.74B | 200.29B | 181.53B |
| Stockholders Equity | 262.17B | 261.56B | 249.25B | 229.45B | 224.50B | 198.56B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 29.77B | 24.24B | -43.72B | -5.90B | 19.51B |
| Operating Cash Flow | 0.00 | 52.37B | 55.83B | -11.80B | 25.99B | 43.31B |
| Investing Cash Flow | 0.00 | -23.48B | -30.41B | -33.76B | -33.80B | -19.28B |
| Financing Cash Flow | 0.00 | -1.11B | -46.51B | 30.15B | 5.12B | -22.53B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | ¥360.35B | 10.71 | 9.65% | 3.91% | 0.87% | 16.71% | |
75 Outperform | ¥292.30B | 23.15 | ― | 1.00% | -3.06% | 45.21% | |
74 Outperform | ¥296.02B | 11.22 | 5.47% | 3.41% | 2.60% | 9.50% | |
63 Neutral | ¥290.54B | 11.46 | 8.86% | 2.65% | -0.04% | 3.15% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
57 Neutral | ¥260.72B | 45.14 | 1.47% | 4.29% | -7.45% | -71.68% | |
55 Neutral | ¥594.20B | -80.57 | -1.15% | 3.49% | -6.83% | -123.67% |
Tokuyama Corporation has lowered its full-year forecast for fiscal 2025, cutting projected net sales from ¥364.5 billion to ¥351.5 billion and reducing expected operating and ordinary profit from ¥41.5 billion to ¥39.0 billion, with profit attributable to owners of the parent revised down from ¥29.0 billion to ¥27.5 billion. The company attributed the downgrade primarily to weaker-than-expected performance through the third quarter, citing declines in domestic and overseas selling prices of chemical products, a development that signals continued pricing pressure in its core markets and a more challenging earnings environment despite profits still expected to exceed fiscal 2024 levels.
The most recent analyst rating on (JP:4043) stock is a Buy with a Yen4989.00 price target. To see the full list of analyst forecasts on Tokuyama stock, see the JP:4043 Stock Forecast page.
Tokuyama reported that while the consolidation of the Tokuyama Life Science Group and solid demand for semiconductor-related products supported revenue, overall net sales declined year on year due to worsening overseas market conditions for vinyl chloride-related products. Operating profit increased compared with the previous year, driven by firm semiconductor-related sales and manufacturing cost improvements, but based on results through the third quarter of fiscal 2025, the company revised its full-year performance forecast downward, signaling a more cautious earnings outlook for stakeholders.
The most recent analyst rating on (JP:4043) stock is a Buy with a Yen4989.00 price target. To see the full list of analyst forecasts on Tokuyama stock, see the JP:4043 Stock Forecast page.
Tokuyama reported third-quarter fiscal 2025 consolidated results showing essentially flat net sales at ¥251.5 billion but a strong improvement in profitability, with operating profit up 26.9% to ¥26.7 billion and profit attributable to owners of parent rising 11.5% to ¥18.9 billion, alongside a jump in comprehensive income and an increase in total assets and shareholders’ equity. The company maintained an aggressive shareholder return stance by raising annual dividend guidance to ¥120 per share from ¥100 in the previous year and announced an upward revision to its full-year fiscal 2025 forecast, now expecting modest sales growth but around 30% gains in operating and ordinary profit and a 17.6% increase in full-year net profit, while expanding its consolidation scope to include seven new life-science-related subsidiaries, a move that signals strategic reinforcement of its medical and biotech portfolio and potentially strengthens its long-term earnings base and industry positioning.
The most recent analyst rating on (JP:4043) stock is a Buy with a Yen4989.00 price target. To see the full list of analyst forecasts on Tokuyama stock, see the JP:4043 Stock Forecast page.
Tokuyama Corporation has announced a leadership reshuffle effective April 1, 2026, as part of the introduction of a new management structure. Current President and Executive Officer Hiroshi Yokota will become Representative Director, Chairman and Executive Officer, while Director and Managing Executive Officer Tomohiro Inoue will be promoted to Representative Director, President and Executive Officer, and Fumiaki Iwasaki will step down from his role as Representative Director while remaining a Director and Senior Managing Executive Officer. Inoue’s appointment reflects a steady internal promotion path through key roles in eco business, cement operations, sustainability, carbon-neutral strategy, and new business development, signaling the company’s intent to further strengthen its strategic focus on environmental solutions, corporate planning, and advanced technology commercialization under the new regime.
The most recent analyst rating on (JP:4043) stock is a Buy with a Yen4910.00 price target. To see the full list of analyst forecasts on Tokuyama stock, see the JP:4043 Stock Forecast page.